KSB 306/7
Alternative Names: KSB 306; KSB 307Latest Information Update: 01 Oct 2002
At a glance
- Originator KS Biomedix Holdings
- Developer KS Biomedix Holdings; Sosei R&D
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Osteoarthritis; Rheumatoid arthritis
Most Recent Events
- 01 Oct 2002 Discontinued - Preclinical for Osteoarthritis in United Kingdom (unspecified route)
- 01 Oct 2002 Discontinued - Preclinical for Rheumatoid arthritis in United Kingdom (unspecified route)
- 25 May 2001 Preclinical development for Osteoarthritis in United Kingdom (Unknown route)